# 00Peptides.com

> The trusted reference for therapeutic peptides. Evidence-based reference for 29 therapeutic peptides across 7 countries (Canada, USA, UK, Australia, New Zealand, Germany, and Mexico). Includes mechanisms, dosing protocols, side effects, and country-specific legal status.

Last updated: 2026-05-19. Editorial team: 00Peptides.com. Medical reviewer: Dr. M. Halvorsen, MD. All content is informational and does not constitute medical advice.

## Core pages

- [Home](https://00peptides.com/): Site overview and entry points
- [Peptides directory](https://00peptides.com/peptides): All 29 peptides
- [Countries directory](https://00peptides.com/countries): All 7 jurisdictions
- [Peptide finder](https://00peptides.com/peptide-finder): Filter by goal, category, and country
- [Articles](https://00peptides.com/blog): Long-form regulatory and clinical guides
- [About](https://00peptides.com/about): Editorial standards
- [Disclaimer](https://00peptides.com/disclaimer): Medical and regulatory disclaimer

## Peptides

- [BPC-157](https://00peptides.com/peptides/bpc-157): Recovery / Healing — Accelerates tendon and ligament healing
- [TB-500](https://00peptides.com/peptides/tb-500): Recovery / Healing — Muscle and connective-tissue recovery
- [Semaglutide](https://00peptides.com/peptides/semaglutide): Metabolic / Weight Loss — Average 15% body-weight loss at 2.4 mg weekly
- [Tirzepatide](https://00peptides.com/peptides/tirzepatide): Metabolic / Weight Loss — Up to ~22.5% body-weight loss at 15 mg (SURMOUNT-1)
- [Retatrutide](https://00peptides.com/peptides/retatrutide): Metabolic / Weight Loss — ~24% body-weight loss at 12 mg in phase 2 at 48 weeks
- [Liraglutide](https://00peptides.com/peptides/liraglutide): Metabolic / Weight Loss — ~8% body-weight loss at 3.0 mg daily over 56 weeks (SCALE)
- [CJC-1295](https://00peptides.com/peptides/cjc-1295): Growth Hormone Secretagogues — Increased lean muscle mass
- [Ipamorelin](https://00peptides.com/peptides/ipamorelin): Growth Hormone Secretagogues — Anti-aging body composition shifts
- [Tesamorelin](https://00peptides.com/peptides/tesamorelin): Growth Hormone Secretagogues — Targeted reduction in visceral adipose tissue
- [Sermorelin](https://00peptides.com/peptides/sermorelin): Growth Hormone Secretagogues — Modest GH and IGF-1 elevation
- [Hexarelin](https://00peptides.com/peptides/hexarelin): Growth Hormone Secretagogues — Strongest acute GH-release of the GHRPs
- [MK-677 (Ibutamoren)](https://00peptides.com/peptides/mk-677): Growth Hormone Secretagogues — Sustained GH and IGF-1 elevation
- [PT-141](https://00peptides.com/peptides/pt-141): Sexual Health — Treats hypoactive sexual desire disorder (HSDD) in premenopausal women
- [Melanotan II](https://00peptides.com/peptides/melanotan-2): Skin / Hair — Skin tanning with reduced UV exposure
- [Epitalon](https://00peptides.com/peptides/epitalon): Longevity / Anti-aging — Restored melatonin secretion in older adults
- [Thymalin](https://00peptides.com/peptides/thymalin): Immune / Anti-inflammatory — Immune restoration in older adults
- [Thymosin Alpha-1](https://00peptides.com/peptides/thymosin-alpha-1): Immune / Anti-inflammatory — Adjuvant for chronic hepatitis B and C
- [GHK-Cu](https://00peptides.com/peptides/ghk-cu): Skin / Hair — Reduced fine lines and improved skin elasticity
- [AOD-9604](https://00peptides.com/peptides/aod-9604): Metabolic / Weight Loss — Targeted fat loss without GH side effects
- [Selank](https://00peptides.com/peptides/selank): Cognitive / Nootropic — Reduces generalised anxiety
- [Semax](https://00peptides.com/peptides/semax): Cognitive / Nootropic — Neuroprotection following ischemic stroke (Russian indication)
- [DSIP](https://00peptides.com/peptides/dsip): Cognitive / Nootropic — Improved deep-sleep quality
- [KPV](https://00peptides.com/peptides/kpv): Immune / Anti-inflammatory — Reduces ulcerative colitis flare severity (preclinical)
- [GHRP-2](https://00peptides.com/peptides/ghrp-2): Growth Hormone Secretagogues — Strong acute GH and IGF-1 elevation
- [GHRP-6](https://00peptides.com/peptides/ghrp-6): Growth Hormone Secretagogues — Strong appetite stimulation (useful for hard gainers)
- [MOTS-c](https://00peptides.com/peptides/mots-c): Longevity / Anti-aging — Improved insulin sensitivity
- [Humanin](https://00peptides.com/peptides/humanin): Longevity / Anti-aging — Neuroprotection in Alzheimer's models
- [Dihexa](https://00peptides.com/peptides/dihexa): Cognitive / Nootropic — Pro-synaptogenic activity in preclinical models
- [Palmitoyl Pentapeptide-4](https://00peptides.com/peptides/palmitoyl-pentapeptide): Skin / Hair — Reduces fine lines and wrinkle depth

## Countries

- [Canada](https://00peptides.com/countries/canada): Regulator HC, currency CAD
- [United States](https://00peptides.com/countries/usa): Regulator FDA, currency USD
- [Australia](https://00peptides.com/countries/australia): Regulator TGA, currency AUD
- [United Kingdom](https://00peptides.com/countries/uk): Regulator MHRA, currency GBP
- [New Zealand](https://00peptides.com/countries/new-zealand): Regulator Medsafe, currency NZD
- [Germany](https://00peptides.com/countries/germany): Regulator BfArM, currency EUR
- [Mexico](https://00peptides.com/countries/mexico): Regulator COFEPRIS, currency MXN

## Articles

- [Are Peptides Legal in Canada? The Complete 2026 Guide](https://00peptides.com/blog/are-peptides-legal-in-canada-2026): Health Canada's framework for therapeutic peptides explained: prescription pathways, compounding pharmacy rules, and the line between approved medicines and research chemicals.
- [Semaglutide vs Tirzepatide in Canada: Which Should You Choose in 2026?](https://00peptides.com/blog/semaglutide-vs-tirzepatide-canada): A direct comparison of Ozempic, Wegovy, Mounjaro, and Zepbound for Canadian patients in 2026: efficacy, side-effect profile, cost, and provincial coverage.
- [BPC-157 in Canada: Legality, Sourcing, and Dosing in 2026](https://00peptides.com/blog/bpc-157-canada-legality-sourcing): Where Canadian patients can legally obtain BPC-157, what compounding pharmacies are dispensing it, and how typical clinical protocols are structured.
- [Best Peptide Clinics in Toronto and Vancouver (2026 Guide)](https://00peptides.com/blog/peptide-clinics-toronto-vancouver-2026): How to evaluate a Canadian peptide clinic in 2026: prescriber credentials, compounding pharmacy partnerships, lab work, and red flags to avoid.
- [How the FDA's 2023 Bulks List Reshaped US Peptide Access](https://00peptides.com/blog/peptides-usa-fda-2023-restrictions): FDA's October 2023 placement of BPC-157, copper peptides, and Thymosin Alpha-1 on the 503A Bulks List Category 2 has restructured American compounding pharmacy access. Here's the 2026 status.
- [Australia's TGA Peptide Prescription Pathway Explained](https://00peptides.com/blog/australia-tga-peptide-prescription-pathway): Schedule 4 classification, the Special Access Scheme, and how Australian patients lawfully access peptides in 2026.
- [Peptides in the UK: NHS, Private Clinics, and the Grey Market](https://00peptides.com/blog/uk-mhra-peptides-private-clinic-2026): How UK patients access GLP-1s through the NHS and private telehealth in 2026, and what the MHRA position is on healing peptides like BPC-157.
- [New Zealand Peptide Access: Medsafe, Pharmac, and Compounding](https://00peptides.com/blog/new-zealand-medsafe-peptides-pharmac): How Medsafe scheduling and Pharmac funding decisions shape Kiwi access to peptides in 2026, including the path to compounded BPC-157 and the funded Ozempic pathway.
- [Peptides in Germany: BfArM Rules and EU Cross-Border Access](https://00peptides.com/blog/germany-bfarm-peptides-eu-rules): How EU directives shape German peptide access through BfArM, why Wegovy is not GKV-reimbursed, and what cross-border options exist for German patients.
- [Mexico Peptide Medical Tourism: A Practical 2026 Guide](https://00peptides.com/blog/mexico-peptide-medical-tourism-guide): Why US and Canadian patients increasingly cross the border for peptide therapy, what COFEPRIS allows, and how to navigate a legitimate Mexican farmacia magistral.
- [Ipamorelin + CJC-1295: The Most Common GH Stack Explained](https://00peptides.com/blog/ipamorelin-cjc-1295-stack-guide): Why Ipamorelin and CJC-1295 are commonly stacked, how they work together, sample protocols, and what realistic outcomes to expect.
- [The Injectable Peptide Safety Checklist Every User Should Know](https://00peptides.com/blog/peptide-safety-checklist-injectable): Cold chain, reconstitution, injection technique, sharps disposal, and red-flag symptoms — a practical safety guide for anyone using injectable peptides under medical supervision.
- [Medicare and GLP-1 Coverage in 2026: Where Things Stand for US Patients](https://00peptides.com/blog/usa-glp1-medicare-coverage-2026): CMS expanded Wegovy coverage for cardiovascular indications in 2024, and the 2026 picture for Medicare Part D, Medicaid, and commercial insurers is now clearer. Here is the practical guide.
- [503B Outsourcing Facilities: A Quiet Pathway for US Peptide Patients](https://00peptides.com/blog/usa-503b-outsourcing-peptide-options): While 503A compounding has narrowed, 503B outsourcing facilities continue to dispense a small set of peptides. Here is what is available, who qualifies, and how prescribers source it.
- [BPC-157 in Australia: Clinic Costs, Compounding, and What to Expect](https://00peptides.com/blog/australia-bpc-157-clinic-costs-2026): How Australian sports medicine and longevity clinics dispense BPC-157 in 2026 — TGA Schedule 4 compliance, typical pricing, monitoring, and the WADA athlete consideration.
- [Wegovy and the PBS in 2026: What Australian Patients Pay](https://00peptides.com/blog/australia-wegovy-pbs-2026-status): Why Wegovy and Mounjaro are not PBS-subsidised for weight loss, what the private pricing looks like in 2026, and which pathways the PBAC may eventually open.
- [Mounjaro Through UK Private Telehealth: A 2026 Buyer's Guide](https://00peptides.com/blog/uk-tirzepatide-private-telehealth-2026): How CQC-regulated UK telehealth providers dispense Mounjaro in 2026: the pharmacy partnerships, monthly pricing, prescribing checks, and the providers worth avoiding.
- [BPC-157 in the UK: Grey-Market Realities and Honest Risks](https://00peptides.com/blog/uk-bpc-157-grey-market-risks-2026): BPC-157 has no legal pathway in the UK. Here is what the grey market looks like in 2026, what the actual risks are, and the safer options for UK patients who feel they need this molecule.
- [Pharmac and Mounjaro in 2026: The Funding Decision Kiwis Have Been Waiting For](https://00peptides.com/blog/new-zealand-pharmac-mounjaro-2026): Pharmac's 2025 review of Mounjaro for type 2 diabetes and weight management — the funding outcome, the Special Authority criteria, and what changes for New Zealand patients in 2026.
- [New Zealand Compounding Pharmacies for Peptides: A 2026 Practitioner's Guide](https://00peptides.com/blog/new-zealand-compounding-pharmacy-peptides): Which Auckland and Wellington compounding pharmacies dispense peptides in 2026, what they compound, typical pricing, and the Medsafe rules that apply.
- [BPC-157 in Germany: The Grey Market and the BfArM Position](https://00peptides.com/blog/germany-grey-market-bpc-157-import): Why BPC-157 has no clean legal pathway in Germany, how the grey market operates inside the EU, and what risks German patients should weigh in 2026.
- [Private Rezept GLP-1s in Germany: 2026 Cost Breakdown](https://00peptides.com/blog/germany-private-rezept-glp-1-cost): What German patients pay for Wegovy and Mounjaro on a private Rezept in 2026, why GKV reimbursement is so restrictive, and how Apotheke pricing varies.
- [Tijuana GLP-1 Pharmacy Guide: A Practical 2026 Cross-Border Walkthrough](https://00peptides.com/blog/mexico-tijuana-glp-1-pharmacy-guide): Step-by-step practical guidance for US patients sourcing branded Wegovy or Mounjaro from Tijuana farmacias in 2026 — prescribers, pricing, US Customs realities, and the pitfalls to avoid.
- [Mexican Farmacia Magistral BPC-157: How Compounded Peptides Work South of the Border](https://00peptides.com/blog/mexico-farmacia-magistral-bpc-157-guide): Inside Mexico's farmacia magistral compounding pharmacy network — what they prepare, COFEPRIS oversight, typical pricing, and how to evaluate quality in 2026.
- [Managing Semaglutide Side Effects: A Patient and Clinician Reference](https://00peptides.com/blog/semaglutide-side-effect-management-guide): Practical management of the common and serious side effects of semaglutide — nausea, constipation, gallbladder, pancreatitis warning signs, muscle loss — drawn from clinical trial data and prescriber experience.
- [Tirzepatide Dosing and Titration: The Real-World Protocol](https://00peptides.com/blog/tirzepatide-dosing-titration-protocol): How tirzepatide is titrated in 2026 clinical practice — the standard 4-week step pattern, the slower titration variations for tolerability, and the dose plateau strategy.
- [BPC-157 vs TB-500: Which Healing Peptide for Which Injury?](https://00peptides.com/blog/bpc-157-vs-tb-500-comparison): Honest comparison of BPC-157 and TB-500 for soft-tissue and joint healing — mechanism differences, the limited human evidence, typical protocols, and the question of stacking.
- [PT-141 (Bremelanotide): Dosing, Safety, and the FDA-Approved Vyleesi Picture](https://00peptides.com/blog/pt-141-bremelanotide-dosing-safety): PT-141 mechanism, FDA-approved Vyleesi vs compounded PT-141, the dosing protocols actually used in clinical practice, and the side-effect realities patients should know.
- [Ipamorelin Side Effects: A Clinical Deep Dive Beyond the Marketing](https://00peptides.com/blog/ipamorelin-side-effects-deep-dive): Ipamorelin is marketed as the cleanest GH secretagogue in clinical use. Here is the honest profile — what side effects actually occur, what the receptor selectivity means in practice, and what to monitor.
- [GHK-Cu Copper Peptide for Skin: Topical Protocols and Honest Expectations](https://00peptides.com/blog/ghk-cu-copper-peptide-skin-protocols): GHK-Cu's mechanism, the topical vs injectable distinction, evidence-based skin protocols, and what realistic results to expect over 8-12 weeks.
- [GLP-1s and Pancreatitis: What the 2026 Evidence Actually Shows](https://00peptides.com/blog/glp-1-pancreatitis-risk-evidence-2026): The pancreatitis question has followed GLP-1 agonists since 2008. Here is the 2026 evidence picture across SUSTAIN, STEP, SURPASS, SURMOUNT, and the major observational cohorts — and what it means for patient decisions.
- [NAD+ Injections vs Peptides: Honest Comparison for Longevity Goals](https://00peptides.com/blog/nad-injections-vs-peptides-comparison): NAD+ and peptide therapies are often marketed alongside each other in longevity clinics. Here is a clear-eyed comparison of mechanisms, evidence, costs, and where each fits.

## Optional

- [Sitemap (XML)](https://00peptides.com/sitemap.xml)
- [Full content (markdown)](https://00peptides.com/llms-full.txt)